Key facts
- Juncell Therapeutics' GC101 TIL therapy met its primary endpoint in a pivotal Phase 2 trial.
- The trial focused on advanced melanoma patients who had previously failed PD-1 antibody treatment.
Juncell Therapeutics' GC101 TIL Therapy Meets Primary Endpoint in Melanoma Trial
IN SHORT
Juncell Therapeutics announced that its GC101 TIL therapy met its primary endpoint in a pivotal Phase 2 trial for advanced melanoma patients who failed PD-1 antibody treatment. The results were presented at the 2026 ASCO Annual Meeting.
Key Numbers
June 1, 2026Presentation date (Chicago time)
2026ASCO Annual Meeting year
Who's Involved
Juncell Therapeutics
Company developing GC101 TIL therapy
GC101 TIL Therapy
Investigational treatment for advanced melanoma
Professor Lu Si
Presented trial results from Peking University Cancer Hospital
2026 ASCO Annual Meeting
Medical conference where results were presented
↳ Why This Matters
The successful outcome of this pivotal trial suggests that Juncell Therapeutics' GC101 TIL therapy could offer a new treatment option for advanced melanoma patients who have exhausted other therapies, potentially impacting the treatment landscape for this aggressive cancer.